After the Hatch-Waxman Act of 1984, pharmaceutical companies were neatly categorized as either brand or generic businesses. Current trends point to the growing need for flexibility and multifaceted approaches to representing clients in pharmaceuticals and biologics patent litigations. Goodwin’s IP Litigation lawyers Daryl Wiesen and Tyler Doh say that because of consolidations, law firms no longer need to pick a side to specialize in and clients don’t need to limit the attorneys they hire for patent litigation. Read the by-line in Bloomberg Law here.
In The Press August 14, 2020